Integrated bioinformatics analysis of aberrantly-methylated differentially-expressed genes and pathways in age-related macular degeneration

Yinchen Shen
  Shanghai General Hospital

Mo Li
  Shanghai Jiao Tong University

Kun Liu
  Shanghai General Hospital

Xiaoyin Xu
  Shanghai General Hospital

Shaopin Zhu
  Shanghai General Hospital

Ning Wang
  Shanghai General Hospital

Wenke Guo
  NHC Key Lab. of Reproduction Regulation

Qianqian Zhao
  NHC Key Lab. of Reproduction Regulation

Ping Lu
  NHC Key Lab. of Reproduction Regulation

Fudong Yu
  NHC Key Lab. of Reproduction Regulation

Xun Xu

Research article

Keywords: Methylation, Gene expression, Enrichment analysis, Network analysis, Age-related macular degeneration

---

Abstract

Background: Age-related macular degeneration (AMD) represents the leading cause of visual impairment in the aging population. The goal of this study was to identify aberrantly-methylated, differentially-expressed genes (MDEGs) in AMD and explore the involved pathways via integrated bioinformatics analysis.

Methods: Data from expression profile GSE29801 and methylation profile GSE102952 were obtained from the Gene Expression Omnibus database. We analyzed differentially-methylated genes and differentially-expressed genes using R software. Functional enrichment and protein–protein interaction (PPI) network analysis were performed using the R package and Search Tool for the Retrieval of Interacting Genes online database. Hub genes were identified using Cytoscape.

Results: In total, 827 and 592 genes showed high and low expression, respectively, in GSE29801; 4117 hyper-methylated genes and 511 hypo-methylated genes were detected in GSE102952. Based on overlap, we categorized 153 genes as hyper-methylated, low-expression genes (Hyper-LGs) and 24 genes as hypo-methylated, high-expression genes (Hypo-HGs). Four Hyper-LGs (*CKB*, *PPP3CA*, *TGFB2*, *SOCS2*) overlapped with AMD risk genes in the Public Health Genomics and Precision Health Knowledge Base. KEGG pathway enrichment analysis indicated that Hypo-HGs were enriched in the calcium signaling pathway, whereas Hyper-LGs were enriched in sphingolipid metabolism. In GO analysis, Hypo-HGs were enriched in fibroblast migration, membrane raft, and coenzyme binding, among others. Hyper-LGs were enriched in mRNA transport, nuclear speck, and DNA binding, among others. In PPI network analysis, 23 nodes and two edges were established from Hypo-HGs, and 151 nodes and 73 edges were established from Hyper-LGs. Hub genes (*DHX9*, *MAPT*, *PAX6*) showed the greatest overlap.

Conclusion: This study revealed potentially aberrantly MDEGs and pathways in AMD, which might improve the understanding of this disease.

Background

Age-related macular degeneration (AMD) is the leading cause of adult blindness in developed countries, particularly in those over 55 years of age. Worldwide, this condition accounts for 7% of cases of blindness [1, 2] and is expected to affect 288 million people by the year 2040 [3]. AMD first appears as drusen (dry AMD) and advances to late AMD (wet AMD) characterized by choroidal neovascularization (CNV) [4]. Drusen is composed of lipoproteinaceous deposits and acellular debris [5]. CNV involves the growth of new abnormal blood vessels originating from the choroid through a break in the Bruch's membrane, which then invade the subretinal pigment epithelium or sub-retinal space, resulting in severe vision loss [6, 7]. AMD affects central fine vision, significantly impairs a patient's ability to drive, read, and recognize faces, and greatly affects quality of life [8]. As for wet-AMD (i.e. advanced stages), anti-vascular endothelial growth factor (anti-VEGF) therapy was shown to be effective and has become the first choice for the treatment of CNV [9]. However, anti-VEGF therapy requires repeated intra-vitreal

injections, which are associated with a risk of infection and treatment burden for both the patients and the ophthalmologists [10]. Moreover, some patients have poor response to the drugs after a long-term treatment [11]. Apart from anti-VEGF drugs, some other therapies have also impacted macular disease treatment and showed their effectiveness, such as dexamethasone implant [12-14].

Previous studies indicated that many environmental factors are associated with an increased risk of AMD, such as age, race, smoking, obesity, and hypertension [15, 16]. Additionally, genetic factors are regarded as important for the initiation and progression of AMD [17, 18]. Comparing to tumor tissue samples, ocular fundus tissue samples (i.e. retina and choroid) of patients with AMD are quite difficult to obtain in real world. The difficulties to obtain human fundus tissues restricted our understanding of this blinding disease. Over the past few years, most genetic studies on AMD were case-control genome-wide association studies (GWASs) of single-nucleotide polymorphisms in the patients' peripheral blood [19-21], which were valuable but provided limited information.

With the rapid development of gene assay technology, studies of disease pathogenesis are no longer limited to gene deletions, gene mutations, and gene insertions, among other changes. Microarrays based on high-throughput platforms are useful and efficient tools to search for meaningful genes and epigenetic alterations for the identification of diagnostic or prognostic biomarkers [22]. To better explore the molecular mechanism underlying AMD, it is necessary to conduct full transcriptome analysis at the tissue level; however, as mentioned previously herein, obtaining ocular tissue samples is difficult. Compared to retina or choroid tissue, blood samples are relatively easy to obtain from patients with AMD. Therefore, it would be helpful to evaluate gene expression in the ocular tissue of patients with AMD as biomarkers in the blood. In the present study, data from gene expression profiling microarrays of human retinal and choroidal samples from the Iowa and Oregon cohort AMD and control donors (GSE29801: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29801) [23], as well as gene methylation profiling microarrays of the peripheral blood of subjects with AMD (GSE102952: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102952), were integrated and analyzed using a series of bioinformatics tools. More precise screening results were obtained by overlapping these two AMD data sets. Few studies have attempted to combine gene expression profile microarrays and gene methylation profile microarrays to understand the development of AMD. The introduction of DNA methylation characteristics in the blood is useful to understand the characteristics of AMD disease at the tissue level.

In the present study, data from gene expression profiling microarrays and gene methylation profiling microarrays were integrated and analyzed. Functional enrichment and protein−protein interaction (PPI) network analyses of screened genes were performed using the R package "clusterProfiler" and Search Tool for the Retrieval of Interacting Genes (STRING) online database. We identified methylated genes in the peripheral blood, which might be useful as biomarkers for the precise diagnosis and treatment of AMD.

Methods

The need for ethics approval was waived by the ethics committee of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (the document is attached as an additional file).

Microarray data information

We identified methylated, differentially-expressed genes (MDEGs) between AMD and control samples by analyzing mRNA microarray and methylation profiling datasets. In this study, a gene expression profiling dataset (GSE29801: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29801) and gene methylation dataset (GSE102952: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102952) were downloaded from the Gene Expression Omnibus (https://www.ncbi. nlm.nih.gov/geo/) of the National Center for Biotechnology Information. The gene expression profiling data were based on the mRNA from the macular regions of human donor eyes from the retina and retinal pigment epithelium (RPE)-choroids. The gene methylation microarray data were assessed using genome-wide DNA methylation profiling of peripheral blood.

Microarray data from GSE29801 included 177 samples from the macular or extramacular regions of human donor eye RPE-choroids and 118 samples from the macular or extramacular region of human donor retinas with no reported ocular disease, with possible preclinical AMD or AMD [23]. RPE-choroid and retinal samples were isolated from human donor eyes obtained from the University of Iowa (GSH) and Lions Eye Bank of Oregon. The Iowa eyes were selected from a well-characterized repository derived from more than 3900 donors. The Oregon eyes were generally classified as AMD based on medical histories confirmed by ophthalmological records [23, 24]. Global transcriptome profiling was carried out using the Agilent Whole Human Genome 4 × 44 K *in situ* oligonucleotide array platform (G4112F, Agilent Technologies, Santa Clara, CA, USA). After removing redundant data, the microarray data of 41 patients with AMD and 42 normal controls were included in our analysis [23]. First, the authors removed redundant data and selected the subjects who had both macular retina and macular RPE-choroid records. Such selection criteria were implemented due to the fact that AMD mainly affects central vision acuity (i.e. the central macular area). Second, we compared the gene expression levels of macular retina and macular RPE-choroid, then, we chose the higher one of them to conduct the further bioinformatics analysis.

For the gene methylation microarray data, Oliver et al. previously performed genome-wide DNA methylation profiling of blood from nine patients with AMD and nine controls based on the GPL13534 Illumina HumanMethylation 450 BeadChip platform (HumanMethylation450_15017482, San Diego, CA, USA), which covers approximately 450,000 CpG sites in different gene regions including the transcription start sites 1500 and 200, 5' untranslated region, 1st exon, body, and 3' untranslated region. The authors generously shared their original data online for public use (GSE102952: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102952). The methylation profile data of all nine patients with AMD and nine normal controls were included in this analysis.

Data processing to identify differentially-expressed genes (DEGs) and differentially-methylated genes (DMGs)

We used the Limma package in R software (version 3.4.2; Bell Laboratories, formerly AT&T, now Lucent Technologies, Murray Hill, NJ, USA) to analyze GSE29801 and GSE102952 to identify DEGs and DMGs. P < 0.05 was regarded as statistically significant. For DEGs, we set the cut-off standard as P < 0.05 and the absolute value of the log (fold-change) > the median (fold-change). For DMGs, we set the cut-off criteria as P < 0.05 and absolute value of log (fold-change) > 3/4 sort [summary log (fold-change)]. For further analysis, hypomethylation-high expression genes (Hypo-HGs) were obtained by overlapping hypomethylated and upregulated genes; hypermethylation-low expression genes (Hyper-LGs) were obtained by overlapping hypermethylated and downregulated genes.

Functional enrichment analysis

Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for the selected genes (Hypo-HGs and Hyper-LGs), and the enrichment results were illustrated using the R package "clusterProfiler". This package can be used to extract biological meaning from large gene lists. We performed GO term enrichment analysis under the following three sub-ontologies: biological process (BP), molecular function (MF), and cellular component (CC). The cut-off criterion of significantly-enriched KEGG pathways was P < 0.05.

Comprehensive PPI network

Determination of the comprehensive PPI network is important to detect the molecular mechanisms of AMD. In this study, we used the online STRING (version 11.0) tool to construct the network of Hypo-HGs and Hyper-LGs. STRING is an online database used to predict PPIs, which are essential to interpret the molecular mechanisms of key cellular activities in AMD. The cut-off standard was defined as an interaction score of 0.4. The results were visualized in Cytoscape software (version 3.5.1). Hub genes were defined as the top three genes that appeared most frequently according to all cytoHubba ranking methods using Cytoscape software. Subsequently, the Molecular Complex Detection (MCODE) algorithm in Cytoscape software was used to screen the modules. An MCODE score > 3 and node number > 3 were used as the criteria to define a module.

Results

Identification of DEGs and DMGs in AMD

To identify DEGs or DMGs, we used the expression profile from GSE29801 (containing RPE-choroid and retina tissue samples from 41 patients with AMD and 42 normal samples) and the methylation profile from GSE102952 (containing peripheral blood samples of nine AMD patients and nine normal controls) after data preprocessing and quality assessment using R software. We identified 827 high-expression genes and 592 low-expression genes and 4117 hypermethylated genes and 511 hypomethylated genes.

The top 100 most significant DEGs of GSE29801 are shown in Table S1, and the top 100 most significant DMGs of GSE102952 are shown in Table S2.

Identification of aberrantly-methylated DEGs in AMD

To further explore the aberrantly-methylated DEGs, Hypo-HGs were obtained by overlapping hypomethylated and upregulated genes, whereas Hyper-LGs were obtained by overlapping hypermethylated and downregulated genes. We identified 24 Hypo-HGs and 153 Hyper-LGs. The flowchart of this study is presented in Figure 1. All genes are shown in Table S3. To confirm the reliability of the results, we compared aberrantly MDEGs from the GSE29801 and GSE102952 datasets with genes in the Public Health Genomics and Precision Health Knowledge Base (PHGKB; version. 5.8) (https://phgkb.cdc.gov/PHGKB/startPagePhenoPedia.action) studied in the category of "macular degeneration"; the results are shown in Figure 2. We screened four Hyper-LGs (*CKB*, *PPP3CA*, *TGFB2*, and *SOCS2*) that overlapped with potential AMD risk genes in the PHGKB. However, no Hypo-HG overlapped in the PHGKB.

Functional enrichment analysis

Functional enrichment analysis was conducted using the R package "clusterProfiler", and all significantly enriched KEGG pathways associated with the 24 Hypo-HGs and 153 Hyper-LGs are shown in Table 1. The results of KEGG pathway enrichment analysis indicated that Hypo-HGs were significantly enriched in the phosphatidylinositol signaling system and calcium signaling pathway, whereas Hyper-LGs were significantly enriched in amphetamine addiction, morphine addiction, and sphingolipid metabolism. The top five GO terms in each category in which the 24 Hypo-HGs and 153 Hyper-LGs were significantly involved are shown in Table 2 and Table 3, respectively. Functional enrichment analysis suggested that the 24 Hypo-HGs were enriched in the BP of fibroblast migration and positive regulation of neurological system process. The GO CC category revealed enrichment in membrane raft and membrane microdomain. The MF category showed enrichment in factors involved in neuropeptide receptor activity and coenzyme binding (Table 2). The 153 Hyper-LGs were enriched in the BP category of mRNA transport, among others. The CC category revealed enrichment in nuclear speck and neuronal cell body, among others. The MF category indicated enrichment in DNA binding and phosphoric ester hydrolase activity (Table 3).

Comprehensive gene regulation network

The STRING database was used to construct PPI networks. Ultimately, 23 nodes and two edges were established from the Hypo-HGs and 151 nodes and 73 edges were established from the Hyper-LGs. The results are shown in Figure 3 and 4. We use Cytoscape software to determine the largest subgroup interaction network of Hyper-LG genes (Figure 5). We identified hub genes using cytoHubba and confirmed that *DHX9*, *MAPT*, and *PAX6* showed the greatest overlap. Two-core module analysis of this subgroup network of Hyper-LG genes was performed, including module1 comprising *HNRNPA3*, *DHX9*, *SRSF11*, and *SLU7* and module2 comprising *SOX1*, *PAX6*, and *DLX2*.

Discussion

AMD is a disease with complex inheritance and epigenetic changes [5]. Identification of the underlying genes has been difficult. Both genomic screening (locational) and candidate gene (functional) approaches have been used. Based on numerous genetic studies of AMD, approximately 50% of the heritability of AMD can be explained by two major loci harboring coding and non-coding variations at chromosomes 1q (*CFH*) and 10q (*ARMS2/HTRA1*) [25-28]. Recently, a large GWAS highlighted new genes and pathways involved in the development of AMD, including complement activation, collagen synthesis, lipid metabolism/cholesterol transport, receptor-mediated endocytosis, endodermal cell differentiation, and extracellular matrix organization, indicating that many unknown genetic changes remain to be identified with respect to the initiation and development of AMD [20]. The application of novel drugs in the treatment of macular disease also indicated the complicated change of the micro-environment of the macular in the case of disease [29-31]. In this study, we screened novel biomarkers by combining microarray information from RPE-choroid and retinal tissue samples from patients with AMD, as well as peripheral blood samples, by overlapping relevant datasets (GSE29801 and GSE10295) using integrated bioinformatics analysis for available microarray data. This is the first study to employ this approach.

The Hyper-LGs identified are potential biomarkers of AMD based on methylation microarrays for pre-clinical detection in peripheral blood. Among them, four Hyper-LGs (*CKB*, *PPP3CA*, *TGFB2*, and *SOCS2*) overlapped with risk genes in the category of "macular degeneration" in the PHGKB. One study revealed that *CKB* is unlikely to explain a significant portion of the risk of developing AMD in a family-based association dataset including 162 families and an independent case-control dataset of 399 cases and 159 fully evaluated controls [32]. *PPP3CA* is a druggable molecule that inactivates MAP3K5 but has not been widely investigated for its role in AMD. One previous study revealed AMD-related sequence variants in genes encoding *PPP3CA*, underlying its relationship with AMD [33]. *TGFB2* induces RPE cell and collagen gel contraction. Subretinal fibrosis contributes to the loss of vision associated with AMD, and RPE cells play a key role in the fibrotic reaction [34]. Under hypoxic conditions, RPE cells can increase the secretion of *TGFB2* and induce epithelial–mesenchymal transition, resulting in the formation of scar-like fibrous tissue in AMD [35]. Targeted inhibition of *TGFB* signaling might be an effective approach to retard AMD progression [36]. SOCS proteins are modulators of cytokine and growth factor signaling, and their aberrant regulation has been linked to a variety of inflammatory and neoplastic diseases [37]. In a GWAS of 919 patients with exudative AMD treated with intravitreal ranibizumab, *SOCS2* was a candidate gene for which levels were associated with visual loss at month three [38]. These results provide insight into AMD pathogenesis but must be confirmed by *in vivo* and *in vitro* experiments. The methylation patterns of *PPP3CA*, *TGFB2*, and *SOCS2* in AMD have not been previously described. We found that these genes were hypermethylated and expressed at low levels, suggesting that the aberrant methylation of these genes affects the pathogenesis of AMD. No Hypo-HGs overlapped in the PHGKB, likely because of the limited number of genes identified.

Among the top five pathways identified by KEGG and GO analyses, calcium signaling [39, 40], sphingolipid metabolism [41, 42], fibroblast migration [43, 44], membrane [45], coenzyme [46-48], and

DNA binding [49] have been investigated in AMD. Calcium signaling, sphingolipid metabolism, and coenzyme categories showed strong relationships with AMD, whereas the others require further evaluation. Calcium signaling plays a vital role in RPE cell function. Intracellular calcium mobilization activates gene expression and the secretion of inflammatory cytokines such as interleukin-8 in human RPE cells [39]. Complement attack on RPE cells, leading to cell death, is also modulated by extracellular calcium and intracellular signaling mechanisms [40]. Sphingosine 1-phosphate is a potent lipid mediator that modulates inflammatory responses and proangiogenic factors, and it has been suggested that this protein upregulates CNV and is deeply involved in the pathogenesis of exudative AMD [42]. Free radicals play a pathogenic role in AMD, whereas coenzyme Q10 has a protective effect [48]. A combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10 was shown to be beneficial for visual functions in early AMD [47]. However, drug metabolism pathways such as amphetamine addiction and morphine addiction could have been identified by chance and might not be related to AMD. The specific manner in which the other pathways affect AMD development and progression must be further investigated.

In the PPI network, 23 nodes and two edges were established from the Hypo-HGs and 151 nodes and 73 edges were established from the Hyper-LGs. *DHX9*, *MAPT*, and *PAX6* were identified as hub genes. Two core modules for Hyper-LGs were structured, including module1 comprising *HNRNPA3*, *DHX9*, *SRSF11*, and *SLU7* and module2 comprising *SOX1*, *PAX6*, and *DLX2*. Among the hub genes and core modules previously mentioned, *PAX6* is expressed in retinal progenitor cells throughout retinogenesis [50]. *PAX6* is a novel regulatory gene among RPE transcription factors that controls the timing of RPE differentiation and adjacent choroid maturation, suggesting that *PAX6* is involved in choroid development during the pathogenesis of AMD [51]. Other genes have not been previously investigated with respect to AMD.

This study aimed to find potential biomarkers of AMD based on public datasets and bioinformatics methods. However, the results of this study were not strong enough to switch the diagnosis and treatment of AMD so far. These years, ophthalmology has experienced significant developments with respect to imaging modalities. Optical coherence tomography (OCT) is a non-invasive imaging modality that produces high-resolution, cross-sectional images of ocular tissues. Compared to time-domain OCT, spectral-domain OCT yields a higher degree of axial resolution and provides more detailed views of intraretinal structure [52]. Swept-source OCT can offer improved images of the choroid and pigmented lesions [53]. The development of OCT benefits to the diagnosis and follow-up of AMD, and we guess the early detection based on MDEGs might help to identify AMD patients before the clinical symptoms appear. It might be possible to develop detection reagents in the blood for early detection and screening of AMD in the future.

There were some limitations of this study. First, we focused on Hyper-LGs and Hypo-HGs without analyzing contra-regulated genes; thus, further analysis is required to evaluate these genes. Second, our study was limited to only two datasets, and we did not conduct validation based on animals or patient samples. Thus, the results are preliminary and larger sample sizes as well as further fundamental experiments are needed to confirm these results. Third, the clinical characteristics of AMD patients

included were not analyzed because these data were not available, and thus, the results should be conservatively interpreted.

Conclusions

In summary, data from gene expression profiling microarrays and gene methylation profiling microarrays of patients with AMD were integrated and analyzed using a series of bioinformatics tools. Our results indicated aberrantly MDEGs (*PPP3CA*, *TGFB2*, and *SOCS2*) and pathways (calcium signaling, sphingolipid metabolism, fibroblast migration, membrane, coenzyme, and DNA binding) associated with AMD. These genes might serve as biomarkers for the precise diagnosis and treatment of AMD. Further studies are needed to confirm the functional significance of the identified genes and pathways in AMD.

Declarations

Ethics approval and consent to participate: All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The written consent was not applicable.

Consent for publication: As the manuscript did not contain any individual details, images or videos, the written consent was not applicable.

Availability of data and materials: The datasets analysed during the current study are available in the Gene Expression Omnibus (GEO, https://www.ncbi. nlm.nih.gov/geo/) of the National Center for Biotechnology Information (NCBI). (GSE29801: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29801; GSE102952: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102952).

Competing interests: The authors declare that they have no competing interests.

Funding: This study was supported by National Key R&D Program of China (2016YFC0904800, 2019YFC0840607), National Natural Science Foundation of China (81800831, 81800799), National Science and Technology Major Project of China (2017ZX09304010) and Shanghai Municipal Commission of Health and Family Planning (201740088). The sponsor or funding organization had no role in the design or conduct of this research.

Authors' contributions: YS conceived and coordinated the project, complied the figures and the tables and wrote the manuscript. ML performed statistical analysis of all data, compiled functional enrichment analysis and protein–protein interaction network analysis. KL, SPZ and XYX helped to coordinate data analysis and screened the hub genes. WG, QZ, PL and NW helped with data curation and searching information in different databases. FY sourced the database and performed statistical analysis of all data. XX conceived and directed the project and wrote the manuscript. All authors reviewed the manuscript.

Acknowledgements: Not applicable.

Abbreviations

AMD: age-related macular degeneration; BP: biological process; CC: cellular component; CNV: choroidal neovascularization; DEGs: differentially expressed genes; DMGs: differentially methylated genes; GEO: Gene Expression Omnibus; GO: Gene ontology; GWASs: genome-wide association studies; Hyper-LGs: hyper-methylated low-expression genes; Hypo-HGs: hypo-methylated high-expression genes; KEGG: Kyoto Encyclopedia of Genes and Genomes; MDEGs: methylated-differentially expressed genes; MF: molecular function; NCBI: National Center for Biotechnology Information; PHGKB: Public Health Genomics and Precision Health Knowledge Base; PPI: protein−protein interaction; RPE: retinal pigment epithelium; STRING: Search Tool for the Retrieval of Interacting Genes

References

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness... JAMA. 2004;291:1900-1.

2. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013;1: e339-49.

3. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106-16.

4. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials. 1999;20:573-600.

5. DeAngelis MM, Owen LA, Morrison MA, Morgan DJ, Li M, Shakoor A, et al. Genetics of age-related macular degeneration (AMD). Hum Mol Genet. 2017;26:R45-50.

6. Jian L, Panpan Y, Wen X. Current choroidal neovascularization treatment. Ophthalmologica. 2013;230:55-61.

7. Do DV. Detection of new-onset choroidal neovascularization. Curr Opin Ophthalmol. 2013;24:244-7.

8. Handa JT. How does the macula protect itself from oxidative stress? Mol Aspects Med. 2012;33:418-35.

9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355: 1419-31.

10. Wang F, Yu S, Liu K, Chen FE, Song F, Zhang X, et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology. 2013; 120: 355−61.

11. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292-9.

12. Iglicki M, Busch C, Zur D, Okada M, Mariussi M, Chhablani JK, et al. DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES: The International Retina Group Real-Life 24-Month Multicenter Study. The IRGREL-DEX Study. Retina. 2019; 39:44-51.

13. Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the 'DR-Pro-DEX Study'. Acta Diabetol. 2018; 55: 541-7.

14. Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A, et al. Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. Ophthalmologica. 2019; 241:9-16.

15. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007;114:253-62.

16. Evans JR., Fletcher AE, Wormald RP. 28,000 Cases of age related macular degeneration causing visual loss in people aged 75 years and above in the United Kingdom may be attributable to smoking. Br J Ophthalmol. 2005;89:550-3.

17. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD. Genetic influence on early age-related maculopathy: a twin study. Ophthalmology. 2002;109:730-6.

18. Shahid H, Khan JC, Cipriani V, Sepp T, Matharu BK, Bunce C, et al. Age-related macular degeneration: the importance of family history as a risk factor. Br J Ophthalmol. 2012;96:427-31.

19. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;45:433-9, 439e1-2.

20. Fritsche LG, Igl W, Bailey JN, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:34-43.

21. Hong N, Shen Y, Yu CY, Wang SQ, Tong JP. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. 2016;94:334-45.

22. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588-99.

23. Newman AM, Gallo NB, Hancox LS, Miller NJ, Radeke CM, Maloney MA, et al. Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks. Genome Med. 2012;4:16.

24. Radeke MJ, Peterson KE, Johnson LV, Anderson DH. Disease susceptibility of the human macula: differential gene transcription in the retinal pigmented epithelium/choroid. Exp Eye Res. 2007;85:366-80.

25. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-9.

26. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-

related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227-32.

27. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitingern T, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14:3227-36.

28. Deangelis MM, Ji F, Adams S, Morrison MA, Harring AJ, Sweeney MO, et al. Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology. 2008;115:1209-15.e7.

29. Zur D, Iglicki M, Loewenstein A. The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Res. 2019; 62: 231-6.

30. Iglicki M, Zur D, Fung A, Gabrielle PH, Lupidi M, Santos R, et al. TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetol. 2019; 56: 1141-7.

31. Zur D, Iglicki M, Sala-Puigdollers A, Chhablani J, Lupidi M, Fraser-Bell S, et al. Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmol. 2019 Aug 17.

32. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, et al. Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci. 2006;47:329-35.

33. SanGiovanni JP, Lee PH. AMD-associated genes encoding stress-activated MAPK pathway constituents are identified by interval-based enrichment analysis. PLoS One. 2013;8:e71239.

34. Kimura K, Orita T, Liu Y, Yang Y, Tokuda K, Kurakazu T, et al. Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist. J Mol Med (Berl). 2015;93:749-58.

35. Feng Z, Li R, Shi H, Bi W, Hou W, Zhang X. Combined silencing of TGF-β2 and Snail genes inhibit epithelial-mesenchymal transition of retinal pigment epithelial cells under hypoxia. Graefes Arch Clin Exp Ophthalmol. 2015;253:875-84.

36. Radeke MJ, Radeke CM, Shih YH, Hu J, Bok D, Johnson LV, et al. Restoration of mesenchymal retinal pigmented epithelial cells by TGFβ pathway inhibitors: implications for age-related macular degeneration. Genome Med. 2015;7:58.

37. Letellier E, Haan S. SOCS2: physiological and pathological functions. Front Biosci (Elite Ed). 2016;8:189-204.

38. Akiyama M, Takahashi A, Momozawa Y, Arakawa S, Miya F, Tsunoda T, et al. Genome-wide association study suggests four variants influencing outcomes with ranibizumab therapy in exudative age-related macular degeneration. J Hum Genet. 2018;63:1083-91.

39. Yang IH, Wong JH, Chang CM, Chen BK, Tsai YT, Chen WC, et al. Involvement of intracellular calcium mobilization in IL-8 activation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2015;56:761-9.

40. Yang P, Baciu P, Kerrigan BC, Etheridge M, Sung E, Toimil BA, et al. Retinal pigment epithelial cell death by the alternative complement cascade: role of membrane regulatory proteins, calcium, PKC,

and oxidative stress. Invest Ophthalmol Vis Sci. 2014;55:3012-21.

41. Pujol-Lereis LM, Liebisch G, Schick T, Lin Y, Grassmann F, Uchida K, et al. Evaluation of serum sphingolipids and the influence of genetic risk factors in age-related macular degeneration. PLoS One. 2018;13:e0200739.

42. Terao R, Honjo M, Aihara M. Apolipoprotein M Inhibits Angiogenic and Inflammatory Response by Sphingosine 1-Phosphate on Retinal Pigment Epithelium Cells. Int J Mol Sci. 2017;19:pii: E112.

43. Theodoropoulou S, Copland DA, Liu J, Wu J, Gardner PJ, Ozaki E, et al. Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye. J Pathol. 2017;241:45-56.

44. Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, et al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008;324:894-901.

45. Kumar-Singh R. The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials. Exp Eye Res. 2019;184:266-77.

46. McGwin G Jr, Modjarrad K, Hall TA, Xie A, Owsley C. 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study. Arch Ophthalmol. 2006;124:33-7.

47. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica. 2005;219:154-66.

48. Blasi MA, Bovina C, Carella G, Genova ML, Jansen AM, Lenaz G, et al. Does coenzyme Q10 play a role in opposing oxidative stress in patients with age-related macular degeneration? Ophthalmologica. 2001;215:51-4.

49. Paimela T, Ryhänen T, Mannermaa E, Ojala J, Kalesnykas G, Salminen A, et al. The effect of 17beta-estradiol on IL-6 secretion and NF-kappaB DNA-binding activity in human retinal pigment epithelial cells. Immunol Lett. 2007;110:139-44.

50. Remez LA, Onishi A, Menuchin-Lasowski Y, Biran A, Blackshaw S, Wahlin KJ, et al. Pax6 is essential for the generation of late-born retinal neurons and for inhibition of photoreceptor-fate during late stages of retinogenesis. Dev Biol. 2017;432:140-50.

51. Cohen-Tayar Y, Cohen H, Mitiagin Y, Abravanel Z, Levy C, Idelson M, et al. Pax6 regulation of Sox9 in the mouse retinal pigmented epithelium controls its timely differentiation and choroid vasculature development. Development. 2018;145:pii: dev163691.

52. Koustenis A Jr, Harris A, Gross J, Januleviciene I, Shah A, Siesky B. Optical coherence tomography angiography: an overview of the technology and an assessment of applications for clinical research. Br J Ophthalmol. 2017; 101:16-20.

53. Francis JH, Pang CE, Abramson DH, Milman T, Folberg R, Mrejen S, et al. Swept-source optical coherence tomography features of choroidal nevi. Am J Ophthalmol. 2015; 159:169-76.e1.

Additional Files

Additional file 1-Table S1. The top 100 most significantly differentially expressed genes (DEGs) of GSE29801. To identify DEGs, we used the expression profile from GSE29801 (containing RPE-choroid and retina tissue samples from 41 patients with AMD and 42 normal samples). After data preprocessing and quality assessment using R software, we identified 827 high-expression genes and 592 low-expression genes. The top 100 most significantly DEGs of GSE29801 are shown in Table S1.

Additional file 2-Table S2. The top 100 most significantly differentially methylated genes (DMGs) of GSE29801. To identify DMGs, we used the methylation profile from GSE102952 (containing peripheral blood samples of 9 AMD patients and 9 normal controls). After data preprocessing and quality assessment using R software, we identified 4117 hypermethylated genes and 511 hypomethylated genes. The top 100 most significantly DMGs of GSE102952 are shown in Table S2.

Additional file 3-Table S3. Identification of aberrantly methylated-differentially expressed genes (DEGs) in age-related macular degeneration (AMD). To further explore the aberrantly methylated DEGs, hypo-methylated, high-expression genes (Hypo-HGs) were obtained by overlapping hypomethylated and up-regulated genes; hyper-methylated, low-expression genes (Hyper-LGs) were obtained by overlapping hypermethylated and down-regulated genes. We identified 24 Hypo-HGs and 153 Hyper-LGs, and all genes are shown in Table S3.

Additional file 4-The statement provided by the ethics committee of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Figures

Figure 1

The flowchart of this study. The data of expression profiling GSE29801 and methylation profiling GSE102952 were obtained from Gene Expression Omnibus (GEO) database. As a result, we identified 827 high-expression genes and 592 low expression genes; 4117 hypermethylated genes and 511 hypomethylated genes. To further explore the aberrantly methylated differentially expressed genes, Hypo-HGs were obtained by overlapping hypomethylation and up-regulated genes; Hyper-LGs were obtained by overlapping hypermethylation and down-regulated genes. In total, we identified 24 Hypo-HGs and 153 Hyper-LGs. Then, functional enrichment analysis and protein−protein interaction (PPI) network analysis of screened genes were performed.

Figure 2

The results of overlapping GSE29801 and GSE102952 datasets with the genes reported to be related to AMD in Public Health Genomics and Precision Health Knowledge Base (PHGKB). (A) Overlapping of hypomethylation-high expression genes (Hypo-HGs) with the genes reported to be related to AMD in PHGKB. (B) Overlapping of hypermethylation-low expression genes (Hyper-LGs) with the genes reported to be related to AMD in PHGKB.

Figure 3

The protein–protein interaction (PPI) networks of the 24 hypomethylation-high expression genes (Hypo-HGs). 23 nodes and 2 edges were established from the Hypo-HGs.

Figure 4

The protein–protein interaction (PPI) networks of the 153 hypermethylation-low expression genes (Hyper-LGs). 151 nodes and 73 edges were established from the Hyper-LGs.

Figure 5

The subgroup protein−protein interaction (PPI) analysis of the hypermethylation-low expression genes (Hyper-LGs).